Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
neurodegenerative diseases
Biotech
Lilly drops 3 clinical programs, including Prevail gene therapy
Lilly discontinued its GRN gene therapy in frontotemporal dementia "due to a lack of compelling efficacy," a spokesperson told Fierce.
Gabrielle Masson
Feb 4, 2026 12:33pm
Cellular energy booster reverses advanced Alzheimer's in mice
Jan 2, 2026 12:42pm
Sanofi signs 2nd biotech deal of the day
Dec 15, 2025 5:50pm
Merck KGaA becomes latest partner for Flagship’s Valo Health
Nov 20, 2025 6:30am
Voyager sets sail on neuro research trek with Transition Bio
Nov 10, 2025 5:23pm
FDA rejects Biohaven approval request, triggering cost cutting
Nov 5, 2025 4:02am
